Sort   by:  
 Page size 
UnknownRandomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Not available
S-EPMC5087315 | biostudies-literature
UnknownWhy Does Knocking Out NACHO, But Not RIC3, Completely Block Expression of α7 Nicotinic Receptors in Mouse Brain?
Not available
S-EPMC7175337 | biostudies-literature
UnknownIdentification of immune signatures associated with both SARS-CoV-2 infection and lung transplantation.
Not available
S-EPMC12432355 | biostudies-literature
UnknownIntegrated antibody language model accelerates IgG screening and design for broad-spectrum antiviral therapy.
Not available
S-EPMC12539245 | biostudies-literature
UnknownNovel antibody language model accelerates IgG screening and design for broad-spectrum antiviral therapy.
Not available
S-EPMC10942297 | biostudies-literature
UnknownNations within a nation: variations in epidemiological transition across the states of India, 1990-2016 in the Global Burden of Disease Study.
Not available
S-EPMC5720596 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Not available
S-EPMC7727327 | biostudies-literature
UnknownEstimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.
Not available
S-EPMC5056319 | biostudies-literature
UnknownSubcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Not available
S-EPMC8362593 | biostudies-literature
UnknownEffect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Not available
S-EPMC8808333 | biostudies-literature
Sort   by:  
 Page size